检验多效药丸背后理论的必要性：印度多效复方制剂研究的理论依据 - Suppr

Suppr

超能文献

The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.

作者信息

Xavier Denis, Pais Prem, Sigamani Alben, Pogue Janice, Afzal Rizwan, Yusuf Salim

机构信息

Department of Pharmacology, St John's Medical College, Bangalore, India.

出版信息

Nat Clin Pract Cardiovasc Med. 2009 Feb;6(2):96-7. doi: 10.1038/ncpcardio1438. Epub 2008 Dec 23.

DOI:10.1038/ncpcardio1438

PMID:19104516

Abstract

摘要

相似文献

The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.

Nat Clin Pract Cardiovasc Med. 2009 Feb;6(2):96-7. doi: 10.1038/ncpcardio1438. Epub 2008 Dec 23.

Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):463-71. doi: 10.1161/CIRCOUTCOMES.111.963637. Epub 2012 Jul 10.

The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct.

Am Heart J. 2018 Dec;206:72-79. doi: 10.1016/j.ahj.2018.07.012. Epub 2018 Aug 2.

Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.

Lancet. 2009 Apr 18;373(9672):1341-51. doi: 10.1016/S0140-6736(09)60611-5. Epub 2009 Mar 30.

Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.

Am J Cardiovasc Drugs. 2010;10(2):95-103. doi: 10.2165/11532170-000000000-00000.

A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.

Eur J Prev Cardiol. 2015 Jul;22(7):920-30. doi: 10.1177/2047487314530382. Epub 2014 Mar 27.

Reflections on the regulation of the Polypill.

Nat Clin Pract Cardiovasc Med. 2009 Feb;6(2):94-5. doi: 10.1038/ncpcardio1416. Epub 2008 Dec 2.

Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.

Eur J Prev Cardiol. 2017 Jun;24(9):951-961. doi: 10.1177/2047487317695616. Epub 2017 Mar 8.

A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.

Trials. 2011 Jan 5;12:3. doi: 10.1186/1745-6215-12-3.

Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial.

Ther Adv Cardiovasc Dis. 2020 Jan-Dec;14:1753944720912071. doi: 10.1177/1753944720912071.

引用本文的文献

QbD-steered HPTLC approach for concurrent estimation of six co-administered COVID-19 and cardiovascular drugs in different matrices: greenness appraisal.

Sci Rep. 2025 Feb 20;15(1):6252. doi: 10.1038/s41598-024-83692-x.

Preventing premature mortality in chronic diseases for South Asians in the UK and beyond.

J R Soc Med. 2009 Nov;102(11):459-63. doi: 10.1258/jrsm.2009.090112.

本文引用的文献

Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data.

Lancet. 2008 Apr 26;371(9622):1435-42. doi: 10.1016/S0140-6736(08)60623-6.

Homocysteine lowering with folic acid and B vitamins in vascular disease.

N Engl J Med. 2006 Apr 13;354(15):1567-77. doi: 10.1056/NEJMoa060900. Epub 2006 Mar 12.

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

Lancet. 2005 Oct 8;366(9493):1267-78. doi: 10.1016/S0140-6736(05)67394-1. Epub 2005 Sep 27.

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.

Lancet. 2003 Nov 8;362(9395):1527-35. doi: 10.1016/s0140-6736(03)14739-3.

Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.

BMJ. 2003 Jun 28;326(7404):1427. doi: 10.1136/bmj.326.7404.1427.

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.

BMJ. 2003 Jun 28;326(7404):1423. doi: 10.1136/bmj.326.7404.1423.

A strategy to reduce cardiovascular disease by more than 80%.

BMJ. 2003 Jun 28;326(7404):1419. doi: 10.1136/bmj.326.7404.1419.

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

Lancet. 2003 Jun 14;361(9374):2005-16. doi: 10.1016/s0140-6736(03)13636-7.

Two decades of progress in preventing vascular disease.

Lancet. 2002 Jul 6;360(9326):2-3. doi: 10.1016/S0140-6736(02)09358-3.

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

BMJ. 2002 Jan 12;324(7329):71-86. doi: 10.1136/bmj.324.7329.71.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验